Pharma Insight ApS: Financial statements 2024
CVR: 40637117
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Pharma Insight ApS (CVR 40637117) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 138,457 and a net result of DKK 117,750 compared with DKK -18,857 the year before. Equity in the 2024 report amounted to DKK 145,095. The solvency ratio was 70.5%.
- Gross Profit
- DKK 138,457
- Profit/Loss
- DKK 117,750
- Equity
- DKK 145,095
- Total Assets
- DKK 205,851
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 138 t. | 118 t. | 145 t. | 0 |
| 2023 | - | -17 t. | -19 t. | 27 t. | 0 |
| 2022 | - | -27 t. | -27 t. | 146 t. | 1 |
| 2021 | - | 725 t. | 48 t. | 273 t. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Pharma Insight ApS has published its annual report for 2023. Gross profit came to DKK -17,122, and the net result was DKK -18,857.
About Pharma Insight ApS
Pharma Insight ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Marianne Kock and Peter Kock. The company is owned by Peter Kock Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 342,207 and a net result of DKK 265,159 compared with DKK 117,750 the year before. Equity in the 2025 report amounted to DKK 340,254.